Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was stopped at interim analysis in August 2011, as stopping criteria for futility were met. There was no statistically significant change on the primary efficacy scale in favor of the drug. There was a very small chance that any additional data could change the study overall outcome. There were no concerns regarding subject safety.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Medically healthy males or females aged 18-65 (inclusive).
Patients must have a primary current diagnosis of MDD without psychotic features.
Patients must be receiving ongoing antidepressant therapy at the time of screening. Duration of the current episode of MDD must be at least 8 weeks prior to enrollment without adequate response to treatment.
You may not be if
Patients with other psychiatric disorders.
Patients who use tobacco products.
Alcohol or substance abuse or dependence.
Treatment with a monoamine oxidase inhibitor within 10 weeks of enrollment.
Pregnancy or breastfeeding.
Clinically significant abnormalities on laboratory tests, electrocardiogram, or physical or neurologic examination.
